
The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.
Summary
The regulatory agency has rejected a highly anticipated cancer treatment from Summit Therapeutics. Officials stated that the medication must demonstrate the ability to extend patient survival before receiving approval.
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Source: Read the full story at MarketWatch.com - Top Stories
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.